del(6q) in Multiple Myeloma

1998-09-01   Christophe Brigaudeau 

1.Laboratory of Hematology, University Hospital, 87000 Limoges, France

Clinics and Pathology

Disease

multiple myeloma (MM) is a malignant plasma cell proliferation

Phenotype stem cell origin

mature differentiated B-cell, but also with CD56 expression, which is not found in normal plasma cell; CD38+, CD40+, CD138+.

Epidemiology

MM s annual incidence is 30/106; del(6q) is observed in about 2 to 5 % of MM cases (i.e. : 5-10 % of cases with an abnormal karyotype).

Clinics

bone pain; susceptibility to infections; renal failure; neurologic dysfonctions

Pathology

MM staging:
- stage I: low tumour cell mass; normal Hb; low serum calcium; no bone lesion; low monoclonal Ig rate;
- stage II: fitting neither stage I nor stage II;
- stage III: high tumour cell mass; low Hb and/or high serum calcium and/or advanced lytic bone lesions and/or high monoclonal Ig rate

Evolution

MM can evolve towards plasma cell leukemia

Prognosis

prognosis (highly variable) is according to the staging and other parameters, of which are now the karyotypic findings : two distinct cytogenetic pattern have been reported, according to the chromosome number : 1- a hyperdiploid pattern, and 2- a pattern of either pseudodiploidy,hypodiploidy or near-tetraploidy karyotypes; patients with the latter pattern appear to have a worse prognosis than patients with a hyperdiploid karyotype (med survival of 1.5 yr vs 3 yrs; p

Genes Involved and Proteins

Note
del(6q) in MM cases encompass the 6q21 band : loss of this band suggests that the critical gene(s) might be a recessive tumour suppressor gene sitting in 6q21, which remains to be identified

Bibliography

Pubmed IDLast YearTitleAuthors
90546681997Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method.Brigaudeau C et al
91159681997Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.Calasanz MJ et al
75371171995Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.Laï JL et al
94732401998Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.Sawyer JR et al
76279331995Cytogenetic findings in 200 patients with multiple myeloma.Sawyer JR et al
96394261998Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.Smadja NV et al

Citation

Christophe Brigaudeau

del(6q) in Multiple Myeloma

Atlas Genet Cytogenet Oncol Haematol. 1998-09-01

Online version: http://atlasgeneticsoncology.org/haematological/2060/del(6q)-in-multiple-myeloma